A new study by Moorfields Eye Hospital and the UCL Institute of Ophthalmology in London shows selective laser trabeculoplasty (SLT) is more successful and more cost-effective for newly diagnosed glaucoma cases than intraocular pressure (IOP) lowering eye drops.
Hello and welcome from the 2019 New Zealand Optometry Student Society (NZOSS) executive.
Hubert Sagnieres, the French executive vice-chairman of eyewear group EssilorLuxottica, hit back at criticism of him by the company’s top shareholder and executive chairman, Italian billionaire
Australians living with, or are at risk of macular disease, will soon benefit from $3 million funding by the Australian government.Announcing the package, Australia's health ministry said it
New Zealand dominated Specsavers’ biennial Excellence Awards, held at the ICC in Sydney’s Darling Harbour in early March.
Registration is now open for O=Mega19, the highly anticipated conference and optical fair, which has replaced the SRC and biennial ODMA fair.
Linda Avison has joined MSO as a sales representative. Previously an optical assistant with Visique Naylor Palmer Optometrists in Palmerston North, Avison is also a florist by trade.
Held each year, over three days in February, MIDO is one of the largest optical fairs in the world. Catering for close to 1400 exhibitors and nearly 60,000 visitors from 159 countries over the three days, the size of this exhibition is truly mind blowing.
Practice owners in Buenos Aires and London’s East End were lauded for their store design at Mido 2019’s annual Bestore Awards.
Macular Degeneration New Zealand’s (MDNZ’s) Professional Friends network profiles member optometrists and ophthalmologists on MDNZ’s website and gives them free access to essential resources, like Amsler grids and nutritional guidance for patients. It also helps cover the cost of MDNZ’s vital public
Look Sharp Eyewear has acquired the Charmant portfolio from Misty Optic and welcomes former Misty Optic and Charmant sales rep, Jamie Smith, to the Look Sharp team.
Inserting a single gene in blind mice gave them back their sight, said scientists, adding the treatment could be being tested in humans in as little as three years. A month after University of
